Medication info
Lometan HCT Tablet 10/40/12.5 Milligrams

Lometan HCT Tablet 10/40/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
Grayish-red round film-coated tablets
Packaging
30 tablets (10 tablets/Alu-Alu × 3)
Approval status
Active

MFDS item code 202002694 · Approved 2020.04.17 · Insurance code 698004610

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual ingredients (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The amounts of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, patients should be monitored very carefully when this medicine is administered.
Child dose
The safety and efficacy of this medicine have not been established in patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension who are not adequately controlling their blood pressure with existing treatments, utilizing a combination of amlodipine and olmesartan medoxomil. The two components work together to dilate blood vessels and effectively lower blood pressure, thus improving hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual ingredients (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The amounts of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, patients should be monitored very carefully when this medicine is administered.

Child dose

The safety and efficacy of this medicine have not been established in patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this drug or its components, those with certain heart, kidney, or liver diseases, pregnant or nursing women, and patients with specific electrolyte imbalances should not take this drug. Patients with reduced blood volume or impaired kidney function, as well as those with liver disease, should be particularly cautious while taking this medication, and their condition should be monitored closely during treatment. As this drug lowers blood pressure, it may cause dizziness or hypotension symptoms, so caution is advised when driving or operating dangerous machinery. Routine monitoring of electrolyte levels in the blood should be conducted during the use of this medication, particularly paying attention to the balance of potassium, sodium, calcium, and magnesium. This medication may interact with other antihypertensives, diuretics, lithium, and non-steroidal anti-inflammatory drugs, so be sure to inform your doctor or pharmacist of any other medications you are taking. Some patients may experience side effects such as skin rash, swelling, headache, dizziness, upper respiratory infections, nasopharyngitis, urinary infections, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia/agranulocytosis, hemolytic anemia, aplastic anemia, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, and hyponatremic. In case of overdose, severe hypotension or cardiac arrhythmias may occur, so care must be taken not to exceed the prescribed dosage, and if overdose is suspected, seek medical attention immediately. The safety and efficacy of this drug in children have not yet been established; therefore, it is recommended that this drug not be given to those under 18 years of age. Elderly patients may have impaired kidney and liver function, so dosage adjustments and precautions are necessary when taking this medication. When storing this medication, keep it in a cool and dry place out of reach of children, and avoid direct sunlight.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity to stimulation, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disturbance, hypertonia, sensory impairment, dysesthesia, peripheral neuropathy, drowsiness, syncope, convulsions, loss of appetite, tremors, visual disturbances, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, distention, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic obstruction, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, papulopustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, recurrence of cutaneous lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urination, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, ennui, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, orbital edema, lethargy, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleed, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome, choroidal effusion

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Grayish-red round film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.